MicroRNA-7 as a Potential Biomarker for Prognosis in Pancreatic Cancer

Figure 1

miRNA expression profiles in the plasma of pancreatic cancer and gemcitabine-resistance samples by statistical analysis of miRNA qRT-PCR array. (a) Heat map of miRNA expression in the serum of pancreatic cancer patients () and healthy controls () was presented in (A). The expression of miR-7 in pancreatic cancer patients () and healthy controls () was measured by qRT-PCR (B). (b) The information of enrolled pancreatic cancer patients. (c) Hierarchical clustering of miRNAs in the serum of the gemcitabine-sensitive group () and the gemcitabine-resistance group () was shown in (A). The miR-7 level of the gemcitabine-sensitive group () was compared to that in the gemcitabine-resistance group () (B). (d) Upregulation of miR-7 sensitized pancreatic cancer cells to gemcitabine. The pancreatic cancer cells were treated with gemcitabine for 24 h after transfected with miR-7 mimics. The viability of the cells was determined by CCK8 assay (A). BxPC-3, MIA PaCa-2, and PANC-1 were treated with gemcitabine (0.1 μM for BxPC-3, 1 μM for MIA PaCa-2, and PANC-1) for 24 h. Assessment of colony formation was performed when upregulation of miR-7 expression (B). ().

(a)

(b)

(c)

(d)